The Ademi Firm is investigating Premier (Nasdaq: PINC) for possible breaches of fiduciary duty and other violations of law in its transaction with Patient Square Capital.
Shareholders of Premier will receive $28.25 per share in a transaction valued at $2.6 billion. Premier insiders will receive substantial benefits as part of change of control arrangements.
The transaction agreement unreasonably limits competing transactions for Premier by imposing a significant penalty if Premier accepts a competing bid. We are investigating the conduct of the Premier board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
Join this Action